Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C13H20N2O3S |
| Molecular Weight | 284.374 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC(=O)\C=C1/SC(N2CCCCC2)C(=O)N1C
InChI
InChIKey=ZCKKHYXUQFTBIK-KTKRTIGZSA-N
InChI=1S/C13H20N2O3S/c1-3-18-11(16)9-10-14(2)12(17)13(19-10)15-7-5-4-6-8-15/h9,13H,3-8H2,1-2H3/b10-9-
| Molecular Formula | C13H20N2O3S |
| Molecular Weight | 284.374 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 1 |
| Optical Activity | ( + / - ) |
Originator
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | ELKAPIN Approved UseUnknown |
|||
Sources: https://www.ncbi.nlm.nih.gov/pubmed/578770 |
Primary | ELKAPIN Approved UseUnknown |
Doses
| Dose | Population | Adverse events |
|---|---|---|
200 mg 1 times / day multiple, oral Studied dose Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Other AEs: Weakness, Epigastric pain... Other AEs: Weakness (3.9%) Sources: Epigastric pain (2.2%) Nausea (1.9%) Constipation (1.7%) Dizziness (1.4%) Headache (1.2%) |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Headache | 1.2% | 200 mg 1 times / day multiple, oral Studied dose Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Dizziness | 1.4% | 200 mg 1 times / day multiple, oral Studied dose Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Constipation | 1.7% | 200 mg 1 times / day multiple, oral Studied dose Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Nausea | 1.9% | 200 mg 1 times / day multiple, oral Studied dose Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Epigastric pain | 2.2% | 200 mg 1 times / day multiple, oral Studied dose Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Weakness | 3.9% | 200 mg 1 times / day multiple, oral Studied dose Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Pharmacodynamics and kinetics of etozolin/ozolinone in hypertensive patients with normal and impaired kidney function. | 1984 |
|
| [Studies on the diuretic effects of etozolin (Elkapin) in heart failure - a comparison with the loop diuretic agent furosemide (author's transl)]. | 1979-04-20 |
|
| [Structure-activity relationships of etozolin, a novel diuretic (author's transl)]. | 1977 |
|
| [On the pharmacology of Etozolin (author's transl)]. | 1977 |
|
| [Toxicological studies on Etozolin (author's transl)]. | 1977 |
|
| [Effect of the diuretic Etozolin (Gö 687) on renal elimination of water and solutes in subjects with normal renal function (author's transl)]. | 1977 |
|
| Distribution of 64Cu-bleomycin in normal and tumor-bearing rats. | 1976-01 |
|
| [LOCALIZATION OF THE SITE OF ACTION OF THE DIURETIC ETOZOLIN IN THE MEPHRON OF THE DOG AND REPORT OF A MATHEMATICAL EVALUATION METHOD OF STOP-FLOW EXPERIMENTS]. | 1964-11-25 |
Patents
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1417365
Isolated rings of guinea-pig aorta were treated with etozolin (10 uM-1 mM). At those concentrations, the drug inhibited noradrenaline- and histamine-induced contractions. At very low concentrations (1 nM-0.1 uM), it inhibited also serotonin-induced contractions.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:27:33 GMT 2025
by
admin
on
Mon Mar 31 18:27:33 GMT 2025
|
| Record UNII |
UEO8UW9V1Z
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C49184
Created by
admin on Mon Mar 31 18:27:33 GMT 2025 , Edited by admin on Mon Mar 31 18:27:33 GMT 2025
|
||
|
WHO-ATC |
C03CX01
Created by
admin on Mon Mar 31 18:27:33 GMT 2025 , Edited by admin on Mon Mar 31 18:27:33 GMT 2025
|
||
|
WHO-VATC |
QC03CX01
Created by
admin on Mon Mar 31 18:27:33 GMT 2025 , Edited by admin on Mon Mar 31 18:27:33 GMT 2025
|
||
|
NCI_THESAURUS |
C270
Created by
admin on Mon Mar 31 18:27:33 GMT 2025 , Edited by admin on Mon Mar 31 18:27:33 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C65600
Created by
admin on Mon Mar 31 18:27:33 GMT 2025 , Edited by admin on Mon Mar 31 18:27:33 GMT 2025
|
PRIMARY | |||
|
200-794-0
Created by
admin on Mon Mar 31 18:27:33 GMT 2025 , Edited by admin on Mon Mar 31 18:27:33 GMT 2025
|
PRIMARY | |||
|
SUB07344MIG
Created by
admin on Mon Mar 31 18:27:33 GMT 2025 , Edited by admin on Mon Mar 31 18:27:33 GMT 2025
|
PRIMARY | |||
|
310039
Created by
admin on Mon Mar 31 18:27:33 GMT 2025 , Edited by admin on Mon Mar 31 18:27:33 GMT 2025
|
PRIMARY | |||
|
DTXSID40874489
Created by
admin on Mon Mar 31 18:27:33 GMT 2025 , Edited by admin on Mon Mar 31 18:27:33 GMT 2025
|
PRIMARY | |||
|
5743585
Created by
admin on Mon Mar 31 18:27:33 GMT 2025 , Edited by admin on Mon Mar 31 18:27:33 GMT 2025
|
PRIMARY | |||
|
95406-04-5
Created by
admin on Mon Mar 31 18:27:33 GMT 2025 , Edited by admin on Mon Mar 31 18:27:33 GMT 2025
|
SUPERSEDED | |||
|
CHEMBL330829
Created by
admin on Mon Mar 31 18:27:33 GMT 2025 , Edited by admin on Mon Mar 31 18:27:33 GMT 2025
|
PRIMARY | |||
|
266-691-8
Created by
admin on Mon Mar 31 18:27:33 GMT 2025 , Edited by admin on Mon Mar 31 18:27:33 GMT 2025
|
ALTERNATIVE | |||
|
1699
Created by
admin on Mon Mar 31 18:27:33 GMT 2025 , Edited by admin on Mon Mar 31 18:27:33 GMT 2025
|
PRIMARY | |||
|
UEO8UW9V1Z
Created by
admin on Mon Mar 31 18:27:33 GMT 2025 , Edited by admin on Mon Mar 31 18:27:33 GMT 2025
|
PRIMARY | |||
|
100000082134
Created by
admin on Mon Mar 31 18:27:33 GMT 2025 , Edited by admin on Mon Mar 31 18:27:33 GMT 2025
|
PRIMARY | |||
|
DB08982
Created by
admin on Mon Mar 31 18:27:33 GMT 2025 , Edited by admin on Mon Mar 31 18:27:33 GMT 2025
|
PRIMARY | |||
|
73-09-6
Created by
admin on Mon Mar 31 18:27:33 GMT 2025 , Edited by admin on Mon Mar 31 18:27:33 GMT 2025
|
PRIMARY | |||
|
Etozolin
Created by
admin on Mon Mar 31 18:27:33 GMT 2025 , Edited by admin on Mon Mar 31 18:27:33 GMT 2025
|
PRIMARY | |||
|
m5204
Created by
admin on Mon Mar 31 18:27:33 GMT 2025 , Edited by admin on Mon Mar 31 18:27:33 GMT 2025
|
PRIMARY | Merck Index | ||
|
C015208
Created by
admin on Mon Mar 31 18:27:33 GMT 2025 , Edited by admin on Mon Mar 31 18:27:33 GMT 2025
|
PRIMARY | |||
|
1114
Created by
admin on Mon Mar 31 18:27:33 GMT 2025 , Edited by admin on Mon Mar 31 18:27:33 GMT 2025
|
PRIMARY | |||
|
67432-21-7
Created by
admin on Mon Mar 31 18:27:33 GMT 2025 , Edited by admin on Mon Mar 31 18:27:33 GMT 2025
|
ALTERNATIVE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ENANTIOMER -> RACEMATE | |||
|
|
ENANTIOMER -> RACEMATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLITE ACTIVE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |